Everolimus for cognition/autism in children with tuberous sclerosis complex: Definitive outcomes deferred

Affiliations

¹ From the Departments of Pediatrics and Neurology (K.C.E.), Vanderbilt University Medical Center, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN; and Departments of Pediatrics and Neurology (D.N.F.), University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, OH.

Editorial

Kevin C Ess et al. Neurology. 2019.

. 2019 Jul 9;93(2):51-52.

doi: 10.1212/WNL.0000000000007744. Epub 2019 Jun 19.

¹ From the Departments of Pediatrics and Neurology (K.C.E.), Vanderbilt University Medical Center, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN; and Departments of Pediatrics and Neurology (D.N.F.), University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, OH.

No abstract available

Comment on

A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex.
Overwater IE, Rietman AB, Mous SE, Bindels-de Heus K, Rizopoulos D, Ten Hoopen LW, van der Vaart T, Jansen FE, Elgersma Y, Moll HA, de Wit MY; ENCORE Expertise Centre for Neurodevelopmental Disorders. Overwater IE, et al. Neurology. 2019 Jul 9;93(2):e200-e209. doi: 10.1212/WNL.0000000000007749. Epub 2019 Jun 19. Neurology. 2019. PMID: 31217257 Clinical Trial.